EU Aduhelm Filing: Biogen Faces Second High-Stakes Meeting At EMA

Biogen needs to explain why its Alzheimer’s disease drug should be approved in the EU, after the European Medicines Agency rejected the product last year.

Aduhelm is Biogen and Eisai's drug for Alzheimer’s disease • Source: Alamy

Biogen was today due to appear before the European Medicines Agency at an oral explanation meeting relating to the regulator’s re-examination of its recommendation last year that the company’s Alzheimer’s disease drug, Aduhelm (aducanumab), should not be approved for use in the EU.

The EMA’s human medicines committee, the CHMP, adopted a negative opinion for the EU marketing authorization application for Aduhelm in...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography